Study of Tarceva and Targretin in Stage I-II Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/10/2019 |
| Start Date: | December 2005 |
| End Date: | August 2010 |
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and
Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by
the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the
treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by
the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the
treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Erlotinib 150mg and bexarotene 400mg/m2 will be administered orally for 7-9 days prior to
thoracotomy. Plasma samples will be collected on the day before surgery and along with tissue
samples on the day of the thoracotomy. Analyses will be done on the resected specimen and it
will be compared to the pre-study diagnostic specimen.
thoracotomy. Plasma samples will be collected on the day before surgery and along with tissue
samples on the day of the thoracotomy. Analyses will be done on the resected specimen and it
will be compared to the pre-study diagnostic specimen.
Inclusion Criteria:
- Resectable stage I or II non-small-cell lung cancer
- Prior tissue biopsy (not cytology) available for research analysis
- Adequate hepatic and renal function
Exclusion Criteria:
- Prior chemotherapy or radiotherapy
We found this trial at
1
site
Click here to add this to my saved trials
